MAINZ BIOMED N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8568 USD | -4.66% |
|
-5.22% | -26.14% |
Financials (USD)
| Sales 2024 * | 1.2M | Sales 2025 * | 2.3M | Capitalization | 18.75M |
|---|---|---|---|---|---|
| Net income 2024 * | -26M | Net income 2025 * | -29M | EV / Sales 2024 * | 15.6 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8.15 x |
| P/E ratio 2024 * |
-0.98
x | P/E ratio 2025 * |
-1.16
x | Employees | 68 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.41% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -4.66% | ||
| 1 week | -5.22% | ||
| Current month | -16.82% | ||
| 1 month | -16.82% | ||
| 3 months | -16.00% | ||
| 6 months | -58.61% | ||
| Current year | -26.14% |
1 week
0.81
1.08
1 month
0.811.13
Current year
0.811.22
1 year
0.816.00
3 years
0.8130.00
5 years
0.8130.00
10 years
0.8130.00
| Managers | Title | Age | Since |
|---|---|---|---|
Guido Baechler
CEO | Chief Executive Officer | 59 | 21-06-30 |
William Caragol
DFI | Director of Finance/CFO | 58 | 21-06-30 |
Corinna Gorges
CTO | Chief Tech/Sci/R&D Officer | - | 21-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregory Tibbitts
BRD | Director/Board Member | 57 | 22-12-13 |
Heiner Dreismann
CHM | Chairman | 69 | 22-12-13 |
| Director/Board Member | 66 | 21-10-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.8568 | -4.66% | 1,085,328 |
| 24-04-24 | 0.8987 | +3.42% | 64,814 |
| 24-04-23 | 0.869 | -0.17% | 75,943 |
| 24-04-22 | 0.8705 | -3.81% | 66,374 |
| 24-04-19 | 0.905 | +0.11% | 62,539 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Calendar
2024-09-03
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.8568
USD
Average target price
2
USD
Spread / Average Target
+133.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.14% | 18.75M | |
| -17.89% | 8.36B | |
| +40.49% | 3.6B | |
| -32.64% | 2.73B | |
| -7.88% | 2.47B | |
| -7.94% | 2.32B | |
| -14.40% | 1.77B | |
| -18.74% | 1.55B | |
| -40.19% | 1.22B | |
| +5.57% | 1.09B |
- Stock Market
- Equities
- MYNZ Stock
